116233-17-1

Basic information

• Product Name: 5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenamine
• Synonyms: 5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenamine;3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-amine
• CAS NO: 116233-17-1
• Molecular Formula: C₁₅H₂₃N
• Molecular Weight: 217.34982
• EINECS: 1806241-263-5
• Mol File: 116233-17-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 321.2 °C at 760 mmHg
• Flash Point: 148.8 °C
• Appearance: /
• Density: 0.938 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenamine(116233-17-1)
• EPA Substance Registry System: 5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenamine(116233-17-1)

Safety Data

• Hazardous Substances Data: 116233-17-1(Hazardous Substances Data)

Usage

General Description

5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenamine is a chemical compound with a complex molecular structure. It belongs to the class of amines and contains five methyl groups, making it highly branched. 5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenamine is a colorless liquid that is used in the manufacturing of various organic compounds and as a reagent in chemical reactions. It is also known for its aromatic properties and is used in the production of fragrances and perfumes. Additionally, it has been studied for its potential applications in medicinal and pharmaceutical fields.

Upstream product

• 116233-16-0 1,2,3,4-tetrahydro-1,1,4,4,6-pentamethyl-7-nitronaphthalene 
• 6683-48-3 1,1,4,4,6-pentamethyl-1,2,3,4-tetrahydronaphthalene 
• 110-03-2 2,5-dimethyl-2,5-hexanediol 
• 108-88-3 toluene 
• 6223-78-5 2,5-dichloro-2,5-dimethyl hexane 

Downstream Products

• 119999-22-3 2-bromo-3-methyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene 
• 214694-11-8 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-ylamino)-benzoic acid ethyl ester 
• 116232-92-9 4-<(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)cerbamoyl>benzoic acid 
• 178264-46-5 N-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl)-2-naphthalenyl 4-ethoxycarbonyl benzaldimine 
• 1227244-08-7 3-nitro-4-[N-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)amino]benzoic acid methyl ester 
• 1416254-96-0 C₂₅H₃₃NO₂ 
• 1416254-97-1 C₂₇H₃₇NO₂ 
• 1416255-01-0 C₂₆H₃₃NO₂ 
• 1416255-02-1 C₂₈H₃₇NO₂ 
• 1416254-91-5 C₂₅H₃₁NO₂ 
• 1416254-92-6 C₂₇H₃₅NO₂ 
• 1422445-95-1 C₂₅H₃₁NO₂ 
• 1227244-12-3 3-amino-4-[N-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)amino]benzoic acid methyl ester 

Relevant articles and documents

Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-yl)amino)nicotinic Acid (NEt-TMN)

Sulfonic acid analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene, 1) as well as seven novel and two reported analogues of 6-(ethyl(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino)nicotinic acid (NEt-TMN) were synthesized and assessed for selective retinoid X receptor (RXR) agonism. Compound 1 is FDA-approved for treatment of cutaneous T-cell lymphoma (CTCL); however, 1 can provoke side effects by impacting RXR-dependent receptor pathways. All of the analogues in this study were evaluated for their potential to bind RXR through modeling and then assayed in an RXR-RXR mammalian-2-hybrid (M2H) system and in RXR-responsive element (RXRE)-mediated transcriptional experiments. The EC50 profiles for these unique analogues and their analogous effectiveness to inhibit proliferation in CTCL cells relative to 1 suggest that these compounds possess similar or even enhanced therapeutic potential. Several compounds also displayed more selective RXR activation with minimal cross-signaling of the retinoic acid receptor. These results suggest that modifications of potent RXR agonists such as NEt-TMN can lead to improved biological selectivity and potency compared with the known therapeutic.

THERAPEUTIC COMPOUNDS

The invention provides compounds and compositions that are useful for treating conditions including Alzheimer's disease, Parkinson's disease, diabetes, cancer, and psychotic disorders such as schizophrenia.

Synthesis and effects of some novel tetrahydronaphthalene derivatives on proliferation and nitric oxide production in lipopolysaccharide activated Raw 264.7 macrophages

In this study, novel N-(3,5,5,8,8-pentamethyl-5,6,7,8- tetrahydronaphthalene-2-yl)-carboxamide (6-15) and 5,5,8,8-tetramethyl-5,6,7,8- tetrahydronaphthalene-2-carboxamide (16-32) derivatives were synthesized and their in vitro effects at 5 μM and 50 μM concentrations on proliferation and nitric oxide (NO) production in lipopolysaccharide (LPS) activated RAW 264.7 macrophage cells were determined. Compounds 12, 17, 24 and 26 were found to decrease nitrite levels in a dose-dependent manner in LPS-activated cells. At the tested concentrations, these compounds did not exhibit cytotoxic effects. Interestingly, compound 27 which contains nitroxide free radical was the most active compound in this series showing 59.2% nitrite inhibition in LPS-activated macrophage cells.